ANXA2 and metabolic dysfunction-associated steatohepatitis: In this study, the results of both bioinformatic analyses and experiments revealed that, the expression level of ANXA2 was up-regulated in both LPS-treated hepatocytes and NASH liver, and the inhibition of ANXA2 expression can suppress the associated hepatocyte pyroptosis and fibrosis.